申请人:Hebeisen Paul
公开号:US20070293509A1
公开(公告)日:2007-12-20
The present invention relates to compounds of the formula I:
wherein R
1
to R
8
are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with the modulation of CB1 receptors, such as obesity.
本发明涉及以下式I的化合物:
其中R1至R8如描述和索赔中定义,并且其药学上可接受的盐。这些化合物对于治疗和/或预防与调节CB1受体相关的疾病,如肥胖症,是有用的。